Evidence map›Paper›PMID 40969209›Full record

ArticleFrontiers in neurology2025

Assessment of Raftlin and blood count parameters in otosclerosis.

Duygu Erdem, Sultan Şevik Eliçora, Berrak Güven, Deniz Baklaci

Abstract read
In one paragraph

Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Duygu ErdemDepartment of Otorhinolaryngology, Faculty of Medicine, Zonguldak Bülent Ecevit University, Zonguldak, Türkiye.
Sultan Şevik EliçoraDepartment of Otorhinolaryngology, Kocaeli City Hospital, Kocaeli, Türkiye.
Berrak GüvenDepartment of Medical Biochemistry, Faculty of Medicine, Zonguldak Bülent Ecevit University, Zonguldak, Türkiye.
Deniz BaklaciDepartment of Otorhinolaryngology, Faculty of Medicine, Zonguldak Bülent Ecevit University, Zonguldak, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Although otosclerosis is a common disease, its etiology has not yet been clearly elucidated. One of the factors recently implicated in its pathogenesis is chronic inflammation. Blood count parameters are known as classical inflammatory markers in several diseases. Raftlin is also a novel biomarker of inflammation. The present study aimed to investigate Raftlin levels and blood count parameters in otosclerosis. Methods: The study included 50 otosclerosis patients and 50 healthy volunteers. Serum Raftlin levels and white blood cell, neutrophil, lymphocyte and platelet counts, neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), and mean platelet volume (MPV) were measured in otosclerosis patients and compared with the controls. Results: White blood cell and neutrophil counts and NLR were statistically higher in otosclerosis patients than in the control group ( Conclusion: The Raftlin level and NLR value were significantly higher in otosclerotic patients than in healthy controls, supporting the presence of an inflammatory etiology for otosclerosis. Our study is the first in the literature to investigate the relationship between otosclerosis and Raftlin with known inflammatory markers.

Indexed as

blood cell counthearing-disordersinflammation mediatorsotosclerosisRaftlin

Identifiers

PMID40969209
PMCPMC12442425

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.